Related Experiment Video
Updated: Mar 2, 2026

Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels
Published on: May 26, 2023
Role of mitral valve repair in active infective endocarditis: long term results
Carlo Rostagno1,2, Enrico Carone3, Pier Luigi Stefàno3
1Dipartimento Medicina sperimentale e clinica, Università di Firenze, Viale Morgagni 85, 50134, Florence, Italy. carlo.rostagno@unifi.it.
Background:
Although mitral valve repair is at present the technique of choice in mitral regurgitation (MR) due to degenerative valve disease, long term results in patients with active mitral infective endocarditis (IE) are still under evaluation.
Methods:
In the study were included 34 consecutive patients (22 males; mean age, 60 years; range 32-84 years) referred to our institution between January 1, 2005 to December 31, 2011 who were treated with valve repair for mitral valve (MV) active infective endocarditis. Eighteen patients underwent isolated MV repair. Aortic valve replacement and respectively repair were performed in 9 and 2 patients with concomitant aortic involvement. Blood cultures were positive in 30 (17 Staphylococcus, 13 Streptococcus, 1 g negative, 2 enterococcus).
Results:
Four patients died during hospital stay (11%) due to multi system organ failure as a consequence of severe septic shock (2 patients), cardiogenic shock (1 case) and respiratory failure (1 patient). At an average follow up of 48 months in patients discharged alive from hospital survival was 96.7% (29 out of 30). None developed more than mild- to moderate mitral valve regurgitation during follow-up and we found a significant improvement in functional capacity and left ventricular ejection fraction associated with a significant decrease of pulmonary artery pressure. The only recurrence of endocarditis occurred in a drug addict patient.
Conclusions:
Present investigation suggest that in patients with active mitral valve endocarditis MV repair, when technically feasible, is associated with a favorable clinical long term outcome. None of the patients alive at the end of follow-up developed severe mitral regurgitation. Moreover mortality and reinfection rate are uncommon and functional improvement.
Insights
Mitral valve repair for active infective endocarditis shows favorable long-term outcomes. Patients experienced improved function and uncommon mortality or reinfection rates, with no severe mitral regurgitation post-procedure.
Area of Science:
- Cardiology
- Cardiac Surgery
- Infectious Diseases
Background:
- Mitral regurgitation (MR) due to degenerative valve disease typically undergoes mitral valve repair.
- Long-term outcomes of mitral valve repair in active mitral infective endocarditis (IE) require further evaluation.
Purpose of the Study:
- To evaluate the long-term clinical outcomes of mitral valve repair in patients with active mitral infective endocarditis.
Main Methods:
- 34 patients with active mitral valve endocarditis underwent mitral valve repair between 2005 and 2011.
- 18 patients had isolated mitral valve repair; others had concomitant aortic valve procedures.
- Positive blood cultures included Staphylococcus, Streptococcus, Gram-negative bacteria, and Enterococcus.
Main Results:
- Hospital mortality was 11% (4 patients) due to septic or cardiogenic shock and respiratory failure.
- Survival at 48-month follow-up was 96.7% for discharged patients.
- No severe mitral regurgitation developed; functional capacity and ejection fraction improved, with decreased pulmonary artery pressure.
Conclusions:
- Mitral valve repair, when feasible, offers favorable long-term outcomes for active mitral valve endocarditis.
- The procedure is associated with low mortality and uncommon reinfection rates.
- Significant functional improvement and absence of severe mitral regurgitation were observed post-repair.
More Related Videos
Related Concept Videos
Endocarditis III: Medical Management
Mitral Stenosis III: Medical Management
Mitral Regurgitation III: Medical Management
Endocarditis I: Introduction
Mitral Stenosis I: Introduction
Mitral Valve Prolapse II: Assessment and Management

